Table 4 Clinical characteristics of 200 patients undergoing laparoscopic gastrectomy.
From: Prognostic impact of pulmonary dysfunction in older gastric cancer patients
Variables | %VC | p value | FEV1.0% | p value | ||
|---|---|---|---|---|---|---|
< 80% (n = 11) | ≥ 80% (n = 189) | < 70% (n = 73) | ≥ 70% (n = 127) | |||
Age, year | 79 (77–82) | 78 (77–81) | 0.440 | 79 (77–81) | 78 (76–81) | 0.117 |
Sex | ||||||
Female | 2 (18.2%) | 46 (24.3%) | 0.632 | 11 (15.1%) | 37 (29.1%) | 0.021* |
Male | 9 (81.8%) | 143 (75.7%) | 62 (84.9%) | 90 (70.9%) | ||
BMI | 20.0 (18.2–21.5) | 23.0 (21.3–24.8) | 0.004* | 23.3 (21.8–24.5) | 22.8 (20.8–24.9) | 0.293 |
CCI | ||||||
0 | 5 (45.5%) | 82 (43.4%) | 0.989 | 33 (45.2%) | 54 (42.5%) | 0.393 |
1, 2 | 5 (45.5%) | 90 (47.6%) | 36 (49.3%) | 59 (46.5%) | ||
≥ 3 | 1 (9.0%) | 17 (9.0%) | 4 (5.5%) | 14 (11.0%) | ||
Smoking history | ||||||
Absence | 4 (36.4%) | 87 (46.0%) | 0.528 | 28 (38.4%) | 63 (49.6%) | 0.122 |
Presence | 7 (63.6%) | 102 (54.0%) | 45 (61.6%) | 64 (50.4%) | ||
History of pulmonary disease | ||||||
Absence | 1 (9.1%) | 8 (4.2%) | 0.500 | 69 (94.5%) | 122 (96.1%) | 0.616 |
Presence | 10 (90.9%) | 181 (95.8%) | 4 (5.5%) | 5 (3.9%) | ||
Surgical procedure a | ||||||
DG | 8 (72.7%) | 119 (62.3%) | 0.758 | 49 (67.1%) | 78 (61.4%) | 0.148 |
PPG | 0 (0.0%) | 4 (2.1%) | 3 (4.1%) | 1 (0.8%) | ||
PG | 1 (9.1%) | 34 (18.0%) | 13 (17.8%) | 22 (17.3%) | ||
TG | 2 (18.2%) | 32 (16.9%) | 8 (11.0%) | 26 (20.5%) | ||
Lymph node dissection | ||||||
D1 | 2 (18.2%) | 18 (9.5%) | 0.397 | 8 (11.0%) | 12 (9.4%) | 0.533 |
D1 + | 6 (54.5%) | 140 (74.1%) | 50 (68.5%) | 96 (75.6%) | ||
D2 | 3 (27.3%) | 31 (16.4%) | 15 (20.5%) | 19 (15.0%) | ||
Intraoperative bleeding, g | 5 (0–30) | 15 (5–49) | 0.090 | 20 (5–64) | 14 (5–39) | 0.108 |
Postoperative complicationb | ||||||
Absence | 9 (81.8%) | 24 (12.7%) | 0.615 | 60 (82.2%) | 114 (89.8%) | 0.131 |
Presence | 2 (18.2%) | 165 (87.3%) | 13 (17.8%) | 13 (10.2%) | ||
Postoperative pneumoniab | ||||||
Absence | 1 (9.1%) | 4 (2.1%) | 0.253 | 70 (95.9%) | 125 (98.4%) | 0.280 |
Presence | 10 (90.9%) | 185 (97.9%) | 3 (4.1%) | 2 (1.6%) | ||
Stage | ||||||
I | 4 (36.4%) | 134 (70.9%) | 0.033* | 53 (72.6%) | 85 (66.9%) | 0.137 |
II | 3 (27.2%) | 37 (19.6%) | 16 (21.9%) | 24 (18.9%) | ||
III | 4 (36.4%) | 18 (9.5%) | 4 (5.5%) | 18 (14.2%) | ||
Adjuvant Chemotherapy | ||||||
Absence | 10 (90.9%) | 163 (86.2%) | 0.643 | 61 (83.6%) | 112 (88.2%) | 0.361 |
Presence | 1 (9.1%) | 26 (13.8%) | 12 (16.4%) | 15 (11.8%) | ||
